Cells expressing mesenchymal/basal phenotypes in tumors have been associated with stem cell properties. Cancer stem cells (CSCs) are often resistant to conventional chemotherapy. We explored overcoming mesenchymal CSC resistance to chemotherapeutic agents. Our goal was to reduce CSC numbers in vivo, in conjunction with chemotherapy, to reduce tumor burden. Analysis of clinical samples demonstrated that COX-2/PGE 2 /EP 4 signaling is elevated in basal-like and chemoresistant breast carcinoma and is correlated with survival and relapse of breast cancer. EP 4 antagonism elicts a striking shift of breast cancer cells from a mesenchymal/CSC state to a more epithelial non-CSC state. The transition was mediated by EP 4 antagonistinduced extracellular vesicles [(EVs)/exosomes] which removed CSC markers, mesenchymal markers, integrins, and drug efflux transporters from the CSCs. In addition, EP 4 antagonism-induced CSC EVs/exosomes can convert tumor epithelial/non-CSCs to mesenchymal/CSCs able to give rise to tumors and to promote tumor cell dissemination. Because of its ability to induce a CSC-to-non-CSC transition, EP 4 antagonist treatment in vivo reduced the numbers of CSCs within tumors and increased tumor chemosensitivity. EP 4 antagonist treatment enhances tumor response to chemotherapy by reducing the numbers of chemotherapy-resistant CSCs available to repopulate the tumor. EP 4 antagonism can collaborate with conventional chemotherapy to reduce tumor burden.
Introduction
Intrinsic tumor chemotherapy resistance is a frequent clinical observation. 1, 2 This resistance is often attributed to the presence of mesenchymal-like cancer stem cells (CSCs), which exhibit heightened resistance to cytotoxic chemotherapy. [3] [4] [5] Passage of neoplastic epithelial cells through an epithelialmesenchymal transition allows these cells to approach a CSC state. 6 In breast cancer, neoplastic cells expressing certain mesenchymal phenotypes, including a stem cell-associated CD44 hi /CD24 lo profile, self-renewal abilities, tumor-initiating abilities and resistance to conventional therapies, 7 have been associated with CSC properties. CSCs are minority populations within tumors; the majority of cancer cells lack tumorinitiating ability. 8 After initially successful chemotherapy, cancers containing a high content of mesenchymal CSCs (e.g, basal-like breast cancer and triple negative breast cancer) 9, 10 exhibit a far shorter disease-free survival and poor overall survival. 11 The small CSC population dominates disease recurrence, metastasis development, and chemotherapy sensitivity. 12 Prostaglandin E 2 (PGE 2 ) is reported to be important for regulation of stem cell homeostasis. In normal tissues PGE 2 plays a key role in maintaining cells in the stem-cell state (e.g., haematopoietic stem cells, mammary stem cells). [13] [14] [15] In cancer, elevated PGE 2 signaling is associated with poor clinical outcome 16 ; PGE 2 signaling affects cell proliferation, survival, angiogenesis, motility and metastasis. 17, 18 Although PGE 2 receptor 4 (EP 4 )-mediated signaling is involved in many CSC-like properties (e.g., CSC marker expression), in normal mammary stem cells. 15 Blocking PGE 2 /EP 4 signaling in mammary stem cells promotes release, via EVs, of mediator molecules characteristic of the stem cell phenotype. Consequently, we suspected PGE 2 -elicited EV removal from CSCs may lead to CSC conversion to an epithelial, non-CSC phenotype. Here we demonstrate that (i) inhibiting EP 4 signaling in CSCs in cancer xenografts reduces the CSC population and intrinsic resistance of CSC population to conventional chemotherapeutics, (ii) CSC EVs can convert epithelial cancer cells to CSCs, and (iii) EP 4 antagonism can enhance chemotherapeutic efficacy for tumor-bearing mice.
Materials and Methods

Cell culture
Human mammary epithelial cells (HMLE) were generated as described. 21 HMLE and NAMEC cells were propagated in MEGM medium (Lonza, CA) MCF-7, MDA-MB-231, HCC1806 and LoVo were obtained from American Type Culture Collection. MCF-7 and MDA-MB-231 cells were grown in DMEM containing 10% fetal bovine serum with penicillin-streptomycin. HCC1806 and LoVo cells were grown in RPMI1640 containing 10% fetal bovine serum with penicillin-streptomycin.
Animal experiments
All research involving animals complied with protocols approved by the NHRI Committee on Animal Care. Sixweek-old female NOD.CB17-Prkdcscid/JNarl mice were obtained from the National Laboratory Animal Center (NLAC, Taiwan). The number of cells, the route of injection and the time for tumor growth are indicated in the figure legends. For MCF-7 xenografts, 17b-Estradiol pellets (0.36 mg, 60-day release, Innovative Research of America) were implanted into the mice one week before MCF-7 cell injection. The tumors were isolated and weighed at the end of each experiment. To measure tumor-initiating cell (TIC) frequency, serial dilutions of tumor cell suspensions were injected subcutaneously into mice. TIC frequencies for the cell samples were determined using the ELDA webtool. 22 
EV/exosome isolation
EVs/exosomes were isolated from cell culture media by differential ultracentrifugation as previously described. 23 Briefly, the culture media were centrifuged at 300 g for 5 min to remove cells (P1), at 2,000 g for 20 min (P2), then at 10,000g for 30 min (P3) all at 48C. Finally, EVs/exosomes (P4) were separated from the supernatant by centrifugation at 110,000g for 60 min. The EV/exosome pellet was washed once in PBS and then resuspended in PBS for further analysis.
Nanoparticle tracking analysis (NTA)
The concentration and size of EVs was measured by nanoparticle tracking analysis (NTA) using a NS300 system (NanoSight). 24 The CM-P4 fractions were suspended in PBS at 20 lg total EV-protein/ml and then were diluted 10,000-fold for NTA analysis. EVs isolated from different conditioned media were suspended in PBS and were diluted into similar concentrations for NTA measurement.
Statistical analysis
Data are presented as mean 6 SEM. A Student's t test was used to compare two groups (p 0.05 was considered significant) unless otherwise indicated. In Figure 6f , panel ii, the tumor growth rate was determined by linear regression. 25 The Tukey test performed a multi-comparison of slopes. p values 0.05 were considered statistically significant. See "Supporting Information Materials and Methods" for more information.
Results
Cyclooxygenase 2 (COX-2)-positive human breast cancer carcinoma cells may be chemotherapy-resistant cancer stem cells (CSCs)
Among the 815 cases of breast invasive carcinoma 26 from
The Cancer Genome Atlas (TCGA) database, 12% have COX-2 gene amplification. A significant difference between survival of the two groups is observed for patients with COX-2 gene amplification (Fig. 1ai) . Overall survival for patients with COX-2 gene amplification is poorer than for patients with no COX-2 gene amplification. The difference is more distinct in patients whose tumors have HER2 1 amplification, a more aggressive cancer type (Fig. 1aii) These observations link COX-2 gene amplification with both poor survival and more rapid disease relapse. In human breast tumors, COX-2 protein is expressed in the more mesenchymal cancer cells that are marked by pancytokeratin (Fig. 1b) and basal cytokeratin 14 (CK14; Fig. 1c) and are located at the outer/basal layer of glandular structures. This finding is supported by mRNA expression profiles from the Oncomine database; breast tumors demonstrating mesenchymal/basal characteristics express elevated COX-2 mRNA levels (Fig. 1d) . 27 These data suggest the elevated level (Fig. 1e) . In contrast, EP 1 , EP 2 , and EP 3 expression was not increased in basal-like breast cancers (Fig. 1e) . Among the EP 1 -EP 4 PGE 2 receptors, only EP 4 expression correlated positively with mesenchymal/basal tumor characteristics. In addition, expression of EP 3 receptor, 29 We previously demonstrated that spontaneously arising NAMECs presented mesenchymal-like, stem-enriched phenotypes (e.g., reduced surface EpCAM and increased mammosphere formation). 15 As anticipated, NAMECs exhibited mesenchymal morphology, losing the characteristic HMLE cell epithelial morphology (Fig. 2a) . In contrast to the HMLE CD44 4 receptor antagonist GW627368X (GW) and assessed stem cell (SC) traits of the control and pharmacologically treated cells. GW is a selective and potent EP 4 receptor antagonist, but has partial affinity for the human TP receptor. 30 Consequently, the highly selective TP receptor antagonist SQ29, 548 (SQ) was also examined, to explore potential TP receptor signaling involvement in the observed phenomena (Supporting Information Fig. S2 ). In an orthologous approach, we blocked PGE 2 /EP 4 signaling in NAMECs with EP 4 receptor shRNAs and assessed SC traits.
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GW treatment induced an epithelial morphology in NAMECs (Fig. 2e) . In contrast, NAMECs cultured in vehicle or SQ maintained their mesenchymal morphology (Fig. 2e) . In addition, the number of invasive cells was decreased 51% by EP 4 antagonist GW but was not affected by TP antagonist SQ (Fig. 2f) . The EP 4 induced decrease in invasive cells was also verified using EP 4 shRNAs (Fig. 2g) ; invasive NAMEC cells were decreased 60% by EP 4 shRNAs (Fig. 2h) .
50% of the NAMEC population mammosphere-forming ability was eliminated by EP 4 antagonist GW (Fig. 2i) . In contrast, TP antagonist SQ did not affect NAMEC mammosphere-forming ability (Fig. 2i) . The effect of blocking EP 4 signaling on decreasing mammosphere-forming ability was orthogonally verified using EP 4 shRNAs (Fig. 2g) ; 30-50% of the NAMEC population's mammosphere-forming ability was eliminated by EP 4 shRNAs (Fig. 2j) . Blocking PGE 2 /EP 4 -mediated signaling by EP 4 antagonist GW or EP 4 shRNAs causes a rapid loss of mesenchymal morphology, invasion ability, and mammosphere-forming ability of basal mammary epithelial stem cells. In contrast, TP receptor antagonist SQ does not have these effects.
In parallel with decreasing stem cell properties, blocking PGE 2 /EP 4 (Fig. 2k) . Large amounts of general exosome markers CD9, CD63, CD81, Alix, TSG101, and GAPDH 32, 33 are present in media from GW-treated NAMECs 31 ( Fig. 2l) . In contrast, exosome markers were not detected in media from SQ-treated NAMECs. EP 4 shRNA blocking of EP 4 signaling confirmed these EV/exosome release results (Figs. 2m and 2n). Blocking PGE 2 /EP 4 signal by the GW EP 4 antagonist induces EV/exosome release from mammary stem cells. This effect is not mediated by the offtarget effect of GW, since blocking EP4 signaling with EP 4 shRNAs induces EV/exosome release and blocking TP receptor-mediated signal does not induce EV/exosome release.
Blocking PGE 2 /EP 4 signaling reduces stem cell properties and tumor-forming capacity of Ras-transformed mesenchymal breast cancer cells
We next turned to investigating whether EP 4 antagonism can reduce breast cancer stem cell (CSC) properties, in a fashion similar to the ability of EP4 antagonism to reduce stem cell properties of normal basal/mesenchymal breast cells. We began by introducing an H-Ras oncoprotein encoding gene into HMLE and NAMEC cells 21 to generate transformed HMLE-R and NAMEC-R cells. MRP4 and EP 4 protein levels were enriched in NAMEC-R cells (Fig. 3a) . In addition, PGE 2 released by NAMEC-R cells was greater than that of HMLE-R cells (Fig. 3b ). While the NAMEC-R mesenchymal phenotype was maintained when cells were treated with vehicle or SQ, EP 4 antagonist GW caused a shift of NAMEC-R cells from a mesenchymal to an epithelial phenotype ( Fig. 3c ). NAMEC-R invasion was decreased by EP 4 antagonist GW pre-treatment (Fig. 3d ). In contrast, TP receptor antagonist SQ did not affect NAMEC-R invasion (Fig. 3d) . NAMEC-R cell tumorsphere formation was reduced by 60% in response to PGE 2 /EP 4 signaling inhibition; SQ inhibition of TP receptor signaling did not affect NAMEC-R tumorsphere-forming ability (Fig. 3e) . Thus, EP 4 antagonist GW eliminates CSC properties in NAMEC-R Ras-transformed mammary basal cells by specifically blocking EP 4 -mediated signaling, not by an effect on TP-mediated signaling.
Blocking PGE 2 /EP 4 signaling elicits release of extracellular vesicles/exosomes and CSC-associated proteins from transformed mesenchymal breast cancer cells
We further investigated whether EP 4 and/or TP receptor antagonism affected EV release from transformed mesenchymal breast cancer cells. EP 4 antagonism elicited release of 5,000 vesicles/NAMEC-R cell. In contrast, only 1,000 vesicles/cell were released from vehicle-or SQ-treated NAMEC-R cells (Fig. 3f) . EV/exosomal markers Alix, TSG101, CD81, and GAPDH 32, 33 were present in substantial amounts in GWtreated NAMEC-R cell media (Fig. 3g) . In contrast, vehicleand SQ-treated NAMEC-R cells produced only marginally detectable exosomal markers in media (Fig. 3g) . The mesenchymal marker N-cadherin and CSC markers CD90 and CD44 were also present in EVs released by GW-treated NAMEC-R cells (Fig. 3h) . These data suggest that removal of mesenchymal GW627368X or SQ 29,548 were added for 4 days prior to initiating tumorsphere assays and were not present during sphere formation. Data are means 6 SEM (n 5 4). ***p 0.001. Scale bar, 500 lm. (f) Quantification of EV/exosome release, shown as the number of particles present per cell in the CM-P4 fractions, from vehicle-treated NAMEC-R cells (Crl), GW627368X-treated NAMEC-R cells (GW, 1 lg/ml GW627368X for 4 days) and SQ 29,548-treated NAMEC-R cells (SQ120/SQ240; 120 and 240 nM for 4 days). Vesicles in the CM-P4 fractions were counted using NTA. Data are means 6 SEM (n 5 6). ***p 0.001. (g) The Alix, TSG101, CD81 and GAPDH exosome markers were measured in the CM-P4 fractions of NAMEC-R cells treated with vehicle (Crl), GW627368X (GW, 1 lg/ml), SQ 29,548 (SQ120/SQ240; 120 and 240 nM). (h) The mesenchymal marker N-cadherin, CSC markers and exosome markers were analyzed in the conditioned medium CM-P4 fractions derived from equal numbers of vehicle-treated NAMEC-R cells (Crl), GW-treated NAMEC-R cells (GW, 1 lg/ml GW627368X for 4 days) and SQ 29,548-treated NAMEC-R cells (SQ120/SQ240; 120 and 240 nM for 4 days). The longer GAPDH(L) and CD81(L) exposures show the low, but detectable, presence of GAPDH and CD81 in the conditioned medium CM-P4 fraction of vehicle-treated NAMEC-R cells. (i) Tumor initiating assay: HMLE-R cells, NAMEC-R cells, or GW627368X-treated (2 weeks) NAMEC-R cells were implanted subcutaneously in NOD/ SCID mice. Mice were euthanized and necropsied after 8 weeks. Tumor initiating frequency is shown as (tumor incidence/number of injected mice) in the pie charts. Frequencies of tumor initiating cells (CSC/TIC frequency) were calculated from the results by using ELDA. (j) Detection of NAMEC-R cell genomic DNA (gDNA) in lungs (top row) and livers (bottom row) of mice with subcutaneous tumors derived from NAMEC-R cells (6 mice) or GW627368X-treated (2 weeks) NAMEC-R cells (6 mice). Lung and liver samples were extracted for genomic DNA determination. NAMEC-R cell gDNA in was detected by PCR that specifically amplifies human GAPDH gDNA. (k) Lung colonization of NAMEC-R cells and GW627368X-treated NAMEC-R cells. The vehicle-treated and GW-treated (1 lg/ml for 10 days) NAMEC-R-dtTomato cells, which were labeled with dtTomato fluorescent protein, were injected into NOD/SCID mice via tail vein. The mice in "MOCK" group were injected in PBS. Mouse lungs were isolated eleven weeks after the injection and lung colonization was monitored by IVIS optical imaging. (l) H&E staining of lung tissues derived from the mice, described in panel k, injected with vehicle-treated (panels i-vi) and GW-treated (panel vii-xii) NAMEC-R-dtTomato cells. Star, tumor colonies. Scale bar, 200 lm. (m) Quantification of lung colonization of NAMEC-R cells and GW-treated NAMEC-R cells. Lung samples isolated from the mice described in panel l were extracted for genomic DNA determination. The existence of NAMEC-R cell genomic DNA in the tissues was detected by PCR that specifically amplifies human GAPDH genomic DNA. The numbers of tumor cells present in 25 mg of lung tissue was determined using a standard curve, as described in "Materials and 
frequency of NAMEC-R CSCs/tumor initiating cells (TICs) by 10-fold by (Fig. 3i) . To analyze whether blocking EP 4 signaling could decrease the ability of mesenchymal/CSC-enriched NAMEC-R cells to spread to distant organs, 5 3 10 6 NAMEC-R cells or GWtreated NAMEC-R cells were implanted subcutaneously in mice. Tumor cell dissemination was analyzed by detection of human genomic DNA in livers and lungs of tumor-bearing mice, using PCR amplification (Supporting Information  Fig. S4 ). Lung disseminated tumor cells (DTCs) were detected in all mice injected with NAMEC-R cells; liver DTCs were detected in 83% of mice injected with NAMEC-R cells (Fig. 3j) . In contrast, lung DTCs were detected in only 33% of mice injected with GW-treated NAMEC-R cells and liver DTCs were detected in only 50% of mice injected with GW-treated NAMEC-R cells (Fig. 3j) .
To investigate whether blocking PGE 2 /EP 4 signaling decreases CSCs capable of forming metastatic colonies in distant organs (e.g., lung), vehicle-and GW-treated NAMEC-RdtTomato cells were injected into mice via tail vein. Lung metastatic colonies and large solid tumors were easily observed in lungs of five mice injected with NAMEC-R cells (Fig. 3k, middle panel and Fig. 3l, panel i-vi, stars) ; no metastatic colonies were found in mice injected with GW-treated NAMEC-R cells (Fig. 3k, right panel and Fig. 3l , panel viixii). Lung metastatic cells were also measured using qPCR of human GAPDH. Cancer cells were detected in lungs of 5/6 mice injected with NAMEC-R cells; the number of tumor cells was 1 3 10 6 cells/25 mg lung tissue (Fig. 3m) (Fig. 4c) . We next examined whether blocking EP 4 signaling can elicit EV-mediated removal of CSC proteins in epithelial MCF-7 and mesenchymal MDA-MB-231 cells (Fig. 4d and EVs/exosomes (231 EV, 1 lg/ml), GW-induced MDA-MB231 EVs/exosomes (GW-in-231 EV, 1 lg/ml), or GW-induced NAMEC EVs/exosomes (GW-in-NA EV, 1 lg/ml). The treatment was suspended during sphere formation. Data are means 6 SEM (n 5 4). *p 0.05, ***p 0.001. Scale bar, 500 lm. (d) Tumor initiating capacity of mesenchymal exosometreated epithelial cells. MCF-7 cells treated with vehicle; with MDA-MB-231 EVs/exosomes (231-EV, 1 lg/ml), with GW-induced MDA-MB-231 EVs/exosomes (GW-in-231-EV, 1 lg/ml), or with GW-induced NAMEC EVs/exosomes (GW-in-NA-EV, 1 lg/ml, 14-day treatment) were implanted subcutaneously in mice. The numbers of cancer cells implanted are indicated in the left column. After 6 weeks, mice were euthanized and necropsied. Tumorigenicity is shown as (tumor incidence/number of injected mice). Tumor initiating cell frequencies were calculated using ELDA. (e) Tumor appearance and weights from the mice described in panel d (the group receiving 1 3 10 5 cells per injection). Data are means 6 SEM. *p 0.05 (f) H&E staining and immunofluorescence analyses for tumors derived from the mice described in panel d (the group receiving 5 3 10 5 cells per injection), using antibodies against vimentin (red), a-smooth muscle actin (red), and ki-67 (green). Cell nuclei were stained with DAPI (blue). Scale bar, 100 lm. Fig. S3b) . In contrast to NAMEC and NAMEC-Ras cells ( Figs. 2k and 3f; 1 3 10 3 EV/cell), breast cancer cells release substantially higher exosome numbers without EP 4 antagonist stimulation ( Fig. 4d ; 5-16 3 10 3 EV/cell). GW EP 4 antagonist treatment of MCF-7 and MDA-MB-231 cells modestly increased the numbers of EVs released by both cell types (Fig. 4d) . However, released protein/cell in the EV/exosome fraction was 10-fold greater for GW-treated MDA-MB-231 cells (Fig. 4e) .
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EP 4 antagonist-elicited MDA-MB231 EV proteins were enriched in CSC markers (CD44, b-catenin), mesenchymal markers (vimentin, fibronectin), and integrins (integrin b1, integrin a6) when compared to proteins present in EP 4 antagonist-elicited MCF-7 EVs/exosomes (Fig. 4f) . CSC markers CD44 and Integrin b1, which were released via EP 4 antagonist-elicited EVs/exosomes, were substantially decreased on the surface of MDA-MB-231 cells in response to GW EP 4 antagonist treatment (Fig. 4g ). In contrast, there was no change in these markers for GW EP 4 antagonist treated MCF-7 cells (Fig. 4g) . Thus, as observed for NAMEC-R cells (Figs. 3f-h ), blocking EP 4 -mediated signaling induced the release of EVs and the removal of CSC-associated proteins from human breast carcinoma cells via EV release.
EP 4 antagonist-treated mesenchymal breast carcinoma cells lose CSC properties as a consequence of EV release
GW treatment reduced the number of invasive MDA-MB-231 cells by 50% (Fig. 4h ) and the number of tumorsphereforming cells by 60% (Fig. 4i) . Since GW treatment did not decrease MDA-MB-231 cell growth (Supporting Information  Fig. S5 ), decreases in cell invasion and tumorsphere formation were not caused by suppression of cell proliferation. Blocking PGE 2 /EP 4 signaling by antagonist GW caused MDA-MB-231 cells to lose these CSC properties.
We next analyzed EP 4 antagonist efficacy in eliciting a CSC-to-non-CSC transition when EV/exosome biogenesis is inhibited. Exosome biogenesis can be blocked at the first step, endocytosis, using the endocytosis-blocking agent Dynasore (Dy). 15 Dy blocked both GW-induced inhibition of invasion (Fig. 4h) and the GW-induced decrease of tumorsphere formation of GW-treated MDA-MB-231 cells (Fig. 4i) . Since Dy treatment did not increase cell growth of GW-treated MDA-MB-231 cells (Supporting Information Fig. S5 ), the Dy increases in cell invasion and tumorsphere formation were not caused by promoting cell proliferation. Blocking EV/exosome biogenesis allowed EP 4 antagonist GW-treated CSCs to preserve their CSC properties. The results suggest that EP 4 antagonism-induced loss of the CSC state from MDA-MB-231 cells requires EV/exosome release.
To investigate whether the EP 4 antagonist-induced EV/ exosome release caused breast mesenchymal carcinoma cells to lose tumor initiating ability, MDA-MB-231 cells pretreated with vehicle, GW EP 4 antagonist, or GW 1 Dy were implanted subcutaneously in mice (Fig. 4j) Fig. 4k and 4l) . However, 88% of the sites implanted with 10 4 GW 1 Dy-treated MDA-MB-231 cells developed tumors ( Fig. 4k and 4l) . The decrease in frequency of CSCs/TICs elicited by GW EP 4 antagonist was fully rescued by blocking EV/exosome biogenesis with Dy (Fig. 4j) . The results demonstrate that EP 4 antagonist GW causes breast carcinoma cells to lose CSC properties as a consequence of EV release.
EP 4 antagonist-elicited CSC EV/exosomes induce tumorinitiating cells in human epithelial-like breast cancer cells
We next investigated whether uptake of EP 4 antagonistelicited CSC EVs/exosomes, which contain molecules associated with the CSC phenotype, can convert non-CSCs into CSCs. HMLE-R non-CSCs were cultured for one week with GW-induced EVs/exosomes from NAMEC-R CSCs. EVs/exosomes from GW-treated NAMEC-R cells increased HMLE-R cell tumorsphere-forming ability (Fig. 5a ). To further demonstrate EV/exosome-mediated transfer of the CSC mesenchymal phenotype, MCF-7 cells were treated with vehicle or with EVs/exosomes isolated from GW-treated NAMEC stem cells (GW-in-NA EV). E-cadherin either disappeared or translocated to the intracellular compartment in GW-in-NA EV treated MCF-7 cells, (Fig. 5b) . CSC EV/exosome ingestion causes epithelial cancer cells to lose their classical epithelial morphology.
We then investigated EP 4 -induced-EV/exosome-mediated transfer of tumorsphere-forming ability and tumor-initiating ability of breast cancer cells. Treatment with MDA-MB-231 cell EVs/exosomes increased slightly MCF-7 cell tumorsphere-forming ability, from 3 spheres/2,000 cells to 13 spheres/2,000 cells (Fig. 5c) . However, treatment of MCF7 cells with EVs/exosomes from GW-treated MDA-MB-231 cells greatly increased tumorsphere formation (40 spheres/ 2,000 cells), as did EVs/exosomes from GW-treated NAMEC cells (50 spheres/2,000 cells; Fig. 5c ).
Only 44% (4/9) of the mice injected with 10 5 untreated
MCF-7 cells or with MCF-7 cells treated with MDA-MB-231
EVs/exosomes formed tumors (Fig. 5d) . In contrast, 100% of the mice injected with 10 5 MCF-7 cells treated with GW-MDA-MB-231 EVs/exosomes with GW-NAMEC EVs/exosomes formed tumors (Fig. 5d) . The number of TICs in tumors derived from epithelial MCF-7 cells is increased 30-fold after treatment with EVs/exosomes from either GWtreated mesenchymal MDA-MB-231 cells or GW-treated mesenchymal NAMECs (Fig. 5d) . The weights of tumors formed by the GW-in-NA EV/exosome-treated MCF-7 cells and the GW-in-231 EV/exosometreated MCF-7 cells are significantly greater than the weights of tumors formed either by untreated MCF-7 cells or by 231 EV/exosome treated MCF-7 cells (Fig. 5e ) These data suggest that EP 4 antagonist-induced EVs/exosomes from CSCs can transfer CSC properties to more epithelial-like non-CSCs, converting the recipients to tumorsphere-forming cells in culture and to TICs in vivo.
Tumor-initiating cells derived by EP 4 antagonist-elicited CSC extracellular vesicles alter tumor stroma and increase tumor proliferation/dissemination in vivo Comparable-sized tumors formed by MCF-7 cells and GWin-NA EV-treated MCF-7 cells were examined histologically (Fig. 5f ). Vimentin staining demonstrated that both tumors contained stromal fibroblasts (Fig. 5f) . a-smooth muscle actin (a-SMA), a marker of myofibroblasts/active fibroblasts, was rarely present in tumors formed by MCF-7 cells (Fig. 5f , lower left panel and Supporting Information Fig. S6, left  panel) ; in contrast, GW-in-NA EV-treated MCF-7 tumors contained abundant a-SMA (Fig. 5f , lower right panel and Supporting Information Fig. S6, right panel) .
Myofibroblasts in tumor stroma can promote tumor cell proliferation. 34 60% of the cells in tumors derived from GWin-NA EV-treated MCF-7 cells, which contained abundant myofibroblasts (indicated by a-SMA-staining), were Ki-67- Figure 6 .
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positive ( Fig. 5f and 5g) . Similarly, 50% of the cells in tumors derived from MCF-7 cells treated with GW-in-231 EVs/exosomes were Ki-67 positive (Fig. 5g) . In contrast, only 20% of cells in tumors derived from MCF-7 cells and from tumors derived from MDA-MB-231 EV-treated MCF-7 cells were Ki-67positive ( Fig. 5f and 5g) . 33% (4/12) of mice injected with MCF-7 cells had lung DTCs; 8% (2/24) had liver DTCs (Fig. 5h) . In contrast, 100% (12/12) of mice injected with GW-in-NA EV-treated MCF-7 cells, had lung DTCs and 38% (9/24) had liver DTCs. EVs/ exosomes derived from GW-treated mesenchymal cancer cells have both greater TIC-inducing ability and greater effectiveness in transferring cell-dissemination capability to recipient cells. Uptake of the CSC EVs/exosomes elicited by EP 4 receptor antagonism induces the transition of non-stem epithelial cancer cells to mesenchymal/stem-like cancer cells; non-stem cancer cells can become TICs after ingestion of GW-induced CSC EVs/exosomes.
EP 4 antagonism reduces cancer stem cell chemoresistance
Stem cells, including CSCs, are rich in transporters able to extrude drugs. This increase in drug transporters may contribute to CSC chemoresistance. 35, 36 We analyzed expression of the Multidrug Resistance-Associated Protein drug transporters (MRP1-4) and Breast Cancer Resistance Protein (BCRP) in human mammary cells, Ras-transformed mammary cells and MCF-7/MDA-MB-231 breast cancer cells (Fig.  6a) . While MRP1 was not detected in these cells, elevated levels of MRP2, MRP3, MRP4 and BCRP were present in stem cell-enriched populations (NAMECs, NAMEC-Ras cells and MDA-MB-231 cells). Stem cell-enriched NAMEC and NAMEC-Ras cells also expressed elevated MRP2, MRP3, and MRP4 levels when compared to HMLE cells (Fig. 6a) . Similarly, CSC-enriched MDA-MB-231 cells expressed increased BCRP, MRP2, MRP3, and MRP4 when compared to MCF-7 cells (Fig. 6a) . EP 4 antagonism decreased levels of drug transporters expressed by mesenchymal SC/CSC-enriched cell populations (Fig. 6a ) and the lost drug transporters were detected in exosomes released by the GW-treated SC/CSCenriched cell populations (Fig. 6a) . These data suggest that EP 4 antagonism may decrease chemoresistance of CSCenriched cell populations by decreasing the levels of drug transporters that efflux chemotherapy agents from cancer stem cells. We next examined the EP 4 antagonist GW effects on CSC viability in response to the chemotherapy agent paclitaxel. CSC-enriched NAMEC-R cells ( Fig. 6b ; red line) are more resistant to paclitaxel than are HMLE-R cells ( Fig. 6b ; green line). GW EP 4 antagonist treatment increased CSC-enriched NAMEC-R cell paclitaxel sensitivity to that of HMLE-R cells ) subcutaneous human tumors (LoVo-GFP or HCC1806-tdTomato) were treated with DMSO vehicle (Crl) or GW627368X (GW, 3 mg/kg. i.p., once-daily) for 3 weeks. Mice were euthanized and necropsied at the end of the treatment. Tumors were isolated and weighed. Data are means 6 SEM (n 5 10). (e) Tumor-initiating assay: GFP/tdTomatolabeled tumor cells isolated from the tumors generated in panel c were implanted subcutaneously, at the numbers shown in the table, in NOD/SCID mice. Mice were euthanized and necropsied after 10 weeks. Tumorigenicity is presented as (tumor incidence/number of injected mice) in the pie charts. CSC/TIC frequencies were calculated, using ELDA. (f) NOD/SCID mice bearing subcutaneous LoVo colorectal cancer xenograft tumors were treated with DMSO vehicle (i.p., once daily), GW627368X (GW, 3 mg/kg. i.p., once-daily), paclitaxel (10 mg/kg, i.p., every other day), or GW627368X 1 paclitaxel for 15 days. Chemotherapy began when tumors were 50 mm 3 . LoVo tumor volume was measured every 3-4 days, using calipers (i). Growth rates were determined by linear regression of data. The slopes of regression lines show the tumor growth rates (ii) for the various treatments. The Tukey test performed a multi-comparison of slopes. Mice were euthanized and necropsied at the end of the treatment, and tumors were isolated and weighed. The final tumor volumes (iii) and final tumor weights (iv) are shown. Data are means 6 SEM (n 7) *p 0.05. **p 0.01. ***p 0.001. (g) NOD/SCID mice bearing subcutaneous HCC1806 triple negative breast cancer xenograft tumors were treated with the same protocol used for LoVo cells. Chemotherapy began when tumors were 150 mm 3 . The treatment was for three weeks. Mice were euthanized and necropsied at the end of the treatment. Tumors were isolated and weighted. Bars are means 6 SEM (n 12). *p 0.05. (h) NOD/SCID mice bearing subcutaneous MDA-MB-231(fLuc) triple negative breast cancer xenograft tumors were treated with the same protocol used for LoVo cells. Tumor growth was monitored by non-invasive bioluminescence imaging. Chemotherapy began when tumors were detected by imaging at 2 weeks after the implantation. Regions of interest were drawn over tumors and total photons were calculated. Tumor growth throughout the course of treatment is presented as "Relative fLuc activity"; the ratio of (luciferase activity at the end of the treatment/luciferase activity just before treatment initiation). Bars are means 6 SEM (n 8). *p 0.05. **p 0.01. ***p 0.001.
( Fig. 6b; black line) . While 27% of the NAMEC-R cells (crl) were resistant to 0.5 nM paclitaxel, only 17% of the GWpretreated NAMEC-R cells were resistant to paclitaxel (Fig.  6c) . In contrast, 32% SQ-pretreated NAMEC-R cells were resistant to paclitaxel (Fig. 6c) ; EP 4 antagonist GW increases CSC chemosensitivity by blocking PGE 2 /EP 4 signaling, not by blocking TP receptor-mediated signaling.
GW-treated NAMEC-R cells were cultured in the absence of GW for one week and were then exposed to paclitaxel (Fig. 6c-trans) . Only 13% of NAMEC-R cells which had been transiently treated with GW were resistant to paclitaxel, suggesting EP 4 antagonist GW increased CSC chemosensitivity lasts for quite some time after EP 4 antagonist withdrawal.
EP 4 antagonists reduce cancer stem cells in tumors
The cell culture results described above suggest EP 4 antagonist-mediated CSC conversion to non-CSCs in tumors might be used to target tumor CSCs by reducing their chemotherapy-resistant subpopulations. To evaluate this hypothesis, NOD/SCID mice bearing subcutaneous HCC1806-tdTomato basal-like breast tumors or LoVo-GFP colorectal tumors were treated with vehicle or with GW for three weeks. GW treatment did not reduce weights for either tumor (Fig. 6d) . CSC/TIC numbers present in these tumors were evaluated by implanting tumor cells at limiting dilutions into NOD/SCID mice. Tumor-initiating frequencies of 5 3 10 Fig. 6e) . In contrast, tumor-initiating frequencies for GW-treated mice were 1/6, 0/6, and 0/6. CSC/TIC frequency in mice bearing vehicle-treated HCC1806-tdTomato tumors was 4.2 3 10
26
, while CSCs/TIC frequency in mice bearing GW-treated HCC1806-tdTomato tumors was 3.3 3 10 27 (Fig. 6e) ; GW treatment decreased CSC frequency in HCC1806-tdTomato tumors by 10-fold. Similar results were observed for LoVo-GFP tumors; EP 4 antagonist treatment caused a 30-fold decrease in CSC number (Fig. 6e) .
EP 4 antagonists reduce tumor chemoresistance in vivo
We suggest that, by reducing the chemotherapy-resistant CSC numbers in tumors, EP 4 agonists may increase efficacy of conventional chemotherapeutic agents. To test this suggestion, mice bearing HCC1806 breast cancer tumors, MDA-MB-231 breast cancer tumors, or LoVo colorectal tumors were treated with DMSO vehicle, GW, paclitaxel, or GW 1 paclitaxel. LoVo tumor xenograft progression in the presence of the combined therapy was significantly reduced when compared to tumor progression in response to either therapy alone ( Fig. 6fi and 6fii ). Only combined GW 1 paclitaxel treatment resulted in significant decreases both in tumor volume and in tumor weight relative to control, untreated tumor-bearing mice ( Fig. 6fiii and 6fiv ).
For HCC1806 tumors, single agent treatment with either paclitaxel or GW had no significant effect on tumor growth (Fig. 6g) . In contrast, combined GW 1 paclitaxel treatment resulted in a significant decrease in tumor weight relative to untreated tumor-bearing mice (Fig. 6g) .
Although, for MDA-MB-231 tumors, single agent paclitaxel therapy decreased MDA-MB-231 tumor growth, GW 1 paclitaxel therapy decreased tumor growth to a greater extent than either single agent (Fig. 6h) . Taken together, these observations demonstrate that systemic EP 4 antagonist treatment can increase the sensitivity of several xenograft human tumors to paclitaxel chemotherapy.
Discussion
Human breast tumors exhibiting a more mesenchymal and CSC-enriched phenotype express elevated COX-2, elevated EP 4 receptor, elevated PGE 2 -transporter MRP4, and elevated PGE 2 release. Elevated MRP4 and EP 4 receptor are oberved in stem cell-enriched populations of normal mammary cells, transformed mammary cells and breast cancer cells; elevated MRP4 and EP 4 receptor appear to be general traits of SC/ CSC-enriched breast cell populations. Blocking PGE 2 /EP 4 signaling of CSC-enriched cell populations decreased CSC surface marker profiles, sphere-forming and tumor-initiating ability, and liver colonization for CSC-enriched populations (Figs. 3 and 4) . Our results extend recent reports by the Fulton and Lala laboratories 20, 37 demonstrating mesenchymal/ CSC-enriched breast tumors have elevated COX-2/PGE 2 /EP 4 signaling.
COX-2 gene amplification is associated with poor survival and disease relapse for breast cancer patients (Fig. 1a) . Park et al. also report survival of breast cancer patients after chemotherapy was significantly decreased if the tumors exhibited elevated COX-2 expression, 38 and Fulton et al. reported that increased MRP4 and decreased 15-PGDH contribute to poor prognosis for breast cancer patients. 39 These observations suggest elevated PGE 2 signaling may result in poor survival and may promote cancer relapse by supporting chemotherapy resistant breast cancer cells. 40 The Fulton and Lala laboratories demonstrated that the presence of EP 4 antagonists suppress cancer cell invasion and tumorsphere-forming ability of breast cancer cells. 20, 37, 41 Their studies were performed in the continued presence of EP 4 antagonists. In contrast, we blocked EP 4 activation during pretreatment and evaluated CSC properties after EP 4 antagonist removal. This protocol decreased mesenchymal breast cancer CSC phenotypes (e.g., invasion ability, tumorsphere-forming ability, tumor-initiating ability, distant site dissemination ability, lung colonization and chemoresistance) by inducing the release of EVs/exosomes that remove mesenchymal (e.g., N-cadherin, vimentin, fibronectin, integrin b1, and integrin a6) and stem cell (e.g., CD44, CD90, and b-catenin) markers, and drug transporters (e.g., BCRP, MRP2, MRP3, MRP4) from CSCs. These data suggest transient EP 4 antagonism-induced CSC EV/exosome release causes long term, perhaps permanent, CSC conversion to non-CSCs. Lala et al. reported COX-2 overexpression induces breast CSCs by up-regulating NOTCH/WNT. 20 In agreement with this observation, we find blocking PGE 2 /EP 4 signaling induced b-catenin removal from breast CSCs via EVs/exosomes.
We previously 15 demonstrated blocking EP 4 signaling (i) induces Rab27b and Rab35 expression essential for increased mammary epithelial stem cell exosome release 42, 43 and (ii) causes protein translocation into lipid rafts which are later sorted into exosomes and released via exosomes. Here we observe that, in contrast to normal mammary epithelial cells, breast cancer cells release substantially higher levels of exosomes without EP 4 antagonist stimulation. EP 4 antagonism increased only slightly numbers of released breast cancer cell exosomes. Compared to normal mammary epithelial cells, Rab27a 44 and Rab27b 45 expression increases in breast cancer cells. Differences in Rab27 protein levels may explain both the high basal levels of exosome release by breast cancer cells and the smaller increases of exosome release induced by EP 4 antagonism for these cells. However, in contrast to the small increase of released exosome numbers, EP 4 antagonism substantially increases exosomal protein contents released via exosomes from breast cancer cells.
EP 4 antagonist-induced CSC exosomes can transfer tumorsphere-forming, tumor-initiating and cancer cell dissemination capabilities to less aggressive, less tumorigenic breast cancer cells (Fig. 5) . Therefore, we suggest the combined use of an EP 4 antagonist, to promote conversion of chemotherapyresistant CSCs to non-CSCs, and use of chemotherapeutic agents to kill both pre-existing and EP 4 antagonist-induced non-CSC tumor cells would prove most efficacious when used in combination (model, Supporting Information Fig. S7iii ). We demonstrated combined paclitaxel and GW treatment was more effective than treatment with either agent alone ( Fig. 6 and Supporting Information Fig. S7i and S7ii) for the three tumor cell lines we tested, suggesting combined reduction of the mesenchymal CSC population and therapy directed at epithelial tumor cells may enhance clinical efficacy of conventional therapies (Supporting Information Fig. S7iii ).
COX-2 inhibitors and NSAIDs have not been widely used in cancer therapy, in part because of concern associated with increases in thrombotic cardiovascular events, for example, myocardial infarction. 46 However, NSAIDs and COX-2 inhibitors have been demonstrated to reduce tumor frequency, progression and metastasis, [47] [48] [49] despite their ability to reduce global prostanoid production and consequently to potentially modulate stem cell biology. EP 4 -specific antagonists are active only on cells with EP 4 receptors-in contrast to more global COX-2 inhibitor effects or NSAIDs that inhibit COX-1 and COX-2. EP 4 antagonism also reduces breast tumor angiogenesis and lymphangiogenesis, consequently decreasing lung metastasis. 50 Given the restricted targeting of EP 4 antagonist activity, compared to the more general inhibition of prostanoid production by NSAIDs and Coxibs, it seems likely that adverse effects in response to EP 4 antagonists are likely to be minimal. We suggest CSC EP 4 antagonism-induced drug transporter elimination via EV/exosomes may play a causal role in enhancing tumor responses to conventional chemotherapy. Our data, and work of others, suggest restricting inhibition of prostanoid signaling to cells expressing EP 4 receptors may provide significant utility in enhancing chemotherapy of epithelial tumors, without evoking the multiple side-effects associated with the widely acting cyclooxygenase inhibitors. These observations suggest EP 4 antagonism, along with conventional chemotherapy, may improve chemotherapeutic efficacy and safety.
